JP2023509388A5 - - Google Patents

Info

Publication number
JP2023509388A5
JP2023509388A5 JP2022538307A JP2022538307A JP2023509388A5 JP 2023509388 A5 JP2023509388 A5 JP 2023509388A5 JP 2022538307 A JP2022538307 A JP 2022538307A JP 2022538307 A JP2022538307 A JP 2022538307A JP 2023509388 A5 JP2023509388 A5 JP 2023509388A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutical composition
composition according
population
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509388A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/087151 external-priority patent/WO2021123255A1/en
Publication of JP2023509388A publication Critical patent/JP2023509388A/ja
Publication of JP2023509388A5 publication Critical patent/JP2023509388A5/ja
Priority to JP2024168495A priority Critical patent/JP2024175144A/ja
Pending legal-status Critical Current

Links

JP2022538307A 2019-12-18 2020-12-18 治療用途の腫瘍浸潤性リンパ球を培養するための改善プロセス Pending JP2023509388A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024168495A JP2024175144A (ja) 2019-12-18 2024-09-27 治療用途の腫瘍浸潤性リンパ球を培養するための改善プロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19217356 2019-12-18
EP19217356.5 2019-12-18
PCT/EP2020/087151 WO2021123255A1 (en) 2019-12-18 2020-12-18 Improved process for culturing tumor-infiltrating lymphocytes for therapeutic use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024168495A Division JP2024175144A (ja) 2019-12-18 2024-09-27 治療用途の腫瘍浸潤性リンパ球を培養するための改善プロセス

Publications (2)

Publication Number Publication Date
JP2023509388A JP2023509388A (ja) 2023-03-08
JP2023509388A5 true JP2023509388A5 (https=) 2023-12-26

Family

ID=68944537

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538307A Pending JP2023509388A (ja) 2019-12-18 2020-12-18 治療用途の腫瘍浸潤性リンパ球を培養するための改善プロセス
JP2024168495A Pending JP2024175144A (ja) 2019-12-18 2024-09-27 治療用途の腫瘍浸潤性リンパ球を培養するための改善プロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024168495A Pending JP2024175144A (ja) 2019-12-18 2024-09-27 治療用途の腫瘍浸潤性リンパ球を培養するための改善プロセス

Country Status (14)

Country Link
US (1) US20230018646A1 (https=)
EP (1) EP4077640B1 (https=)
JP (2) JP2023509388A (https=)
KR (1) KR20220119080A (https=)
CN (1) CN114929861A (https=)
AU (1) AU2020408201A1 (https=)
BR (1) BR112022011702A2 (https=)
CA (1) CA3161510A1 (https=)
DK (1) DK4077640T3 (https=)
ES (1) ES2984777T3 (https=)
IL (1) IL293874B2 (https=)
MX (1) MX2022007416A (https=)
PH (1) PH12022551495A1 (https=)
WO (1) WO2021123255A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
CN116421720A (zh) * 2023-04-26 2023-07-14 乔国梁 抗肿瘤联用细胞产品和抗肿瘤细胞产品
CN118853565A (zh) * 2024-09-14 2024-10-29 青岛华赛伯曼医学细胞生物有限公司 一种肿瘤浸润淋巴细胞的培养工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103374548A (zh) * 2012-04-27 2013-10-30 上海诺昊亚医学诊断技术有限公司 一种肿瘤浸润淋巴细胞的高效扩增培养液
WO2015157636A1 (en) * 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
CN110520530A (zh) * 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
KR102618948B1 (ko) * 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
EP3707245A1 (en) * 2017-11-06 2020-09-16 Ludwig Institute for Cancer Research Ltd Method for expansion of lymphocytes

Similar Documents

Publication Publication Date Title
Daher et al. CAR‐NK cells: the next wave of cellular therapy for cancer
Shin et al. NK cell-based immunotherapies in cancer
Atilla et al. The black hole: CAR T cell therapy in AML
CN107922925B (zh) 用于自然杀伤细胞扩增的方法
Taniguchi et al. Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy
JP2023509388A5 (https=)
Pinchuk et al. Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells
EP3770251A1 (en) Method for producing natural killer cells
Khammari et al. Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients
Cany et al. Umbilical cord blood–derived cellular products for cancer immunotherapy
WO2013167136A1 (en) Improving adoptive cell therapy with interferon gamma
JP2022524882A5 (https=)
Guo et al. Proliferation of highly cytotoxic human natural killer cells by OX40L armed NK-92 with secretory neoleukin-2/15 for cancer immunotherapy
JP2021516666A5 (https=)
Dashtsoodol et al. Natural killer T cell-targeted immunotherapy mediating long-term memory responses and strong antitumor activity
Tassi et al. Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients
Mosna The immunotherapy of acute myeloid leukemia: A clinical point of view
Li et al. Back to the future: spatiotemporal determinants of NK cell antitumor function
Li et al. Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells
ES2383418T3 (es) Agente celular antiangiogénico para la terapia del cáncer.
Su et al. Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells
KR20240011756A (ko) 종양 침윤 t-림프구(til)의 생산 방법 및 인간 종양 치료를 위한 세포 치료제로서의 이의 용도
Azevedo et al. Current landscape of clinical use of ex vivo expanded natural killer cells for cancer therapy
JP2022541925A5 (https=)
CN110205293A (zh) 一种加强型高效治疗肺癌的nk免疫细胞的制备方法及应用